# Special Issue

# Gastrointestinal and Its Associated Malignancies: Diagnosis, Targets and Therapies

### Message from the Guest Editors

Gastrointestinal cancers constitute a heterogenous and aggressive group of malignancies characterized by high relapse rates. They are ranked as the third-leading cause of cancer-related deaths, and this emphasizes the pressing need for advancements in both their diagnosis and treatment strategies. Unfortunately, a significant number of patients face late-stage diagnoses due to the unremarkable nature of early symptoms and the limited prevalence of regular screenings. Diagnostic procedures include a range of techniques such as endoscopy, barium swallow, CT, NMR, PET/CT scans, and biomarker testing, as well as MRI with gadolinium and laparoscopy. This delayed identification, coupled with the constraints of available therapies, contributes to a grim prognosis, especially for individuals with advanced gastric cancer, resulting in a short lifespan of approximately one year. Standard treatment modalities involve radiotherapy, chemotherapy, and targeted therapy, yet their effectiveness is impeded by challenges like multi-drug resistance and tumor relapse.

### **Guest Editors**

Dr. Ganji P. Nagaraju

Division of Hematology & Oncology—Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA

#### Dr. Seema Kumari

Department of Biochemistry and Bioinformatics, GIS, GITAM (Deemed to Be University), Visakhapatnam 530045, India

### Deadline for manuscript submissions

1 December 2025



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/195712

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

